%22%2F%3E%0A%20%20%3Cpath%20d%3D%22M0%20706%20L1536%20432%20L1536%201024%20L0%201024%20Z%22%20fill%3D%22%23f3f5f7%22%20opacity%3D%220.18%22%2F%3E%0A%20%20%3Cpath%20d%3D%22M1060%200%20L1536%200%20L1536%201024%20L1250%201024%20Z%22%20fill%3D%22%23cc0000%22%20opacity%3D%220.38%22%2F%3E%0A%20%20%3Crect%20x%3D%2284%22%20y%3D%2288%22%20width%3D%22210%22%20height%3D%2218%22%20fill%3D%22%23cc0000%22%2F%3E%0A%20%20%3Ctext%20x%3D%2284%22%20y%3D%22164%22%20fill%3D%22%23ffffff%22%20font-family%3D%22Arial%2C%20Helvetica%2C%20sans-serif%22%20font-size%3D%2264%22%20font-weight%3D%22900%22%3EWORLD%3C%2Ftext%3E%0A%3C%2Fsvg%3E)
world
Australian Government Secures Continued PBS Listing for Key MS Drugs Amid Pricing Dispute
Health Minister Mark Butler confirms Ocrevus, Kesimpta, and Lemtrada will remain subsidised on the Pharmaceutical Benefits Scheme while a rapid review is conducted.